What is the recommended inpatient management—including opioid withdrawal treatment, psychopharmacologic regimen, and safety planning—for a patient presenting with suicidal ideation secondary to opioid (kratom) withdrawal, who has a history of depression, anxiety, bipolar disorder, prior self‑injurious behavior, and polysubstance use?

Recommended Inpatient Management for Kratom Withdrawal with Suicidal Ideation

This patient requires immediate psychiatric stabilization with buprenorphine-naloxone for opioid withdrawal management, cognitive behavioral therapy focused on suicide prevention, and mood stabilization with consideration of clozapine if psychotic features emerge, while maintaining continuous suicide precautions.

Opioid Withdrawal Treatment

Initiate buprenorphine-naloxone as the primary treatment for kratom-induced opioid withdrawal. Kratom's active alkaloids (mitragynine and 7-hydroxymitragynine) act as μ-opioid receptor agonists, producing withdrawal syndromes clinically indistinguishable from traditional opioids 1, 2, 3. Buprenorphine-naloxone has demonstrated efficacy in managing kratom dependence while simultaneously addressing chronic pain, depression, and anxiety symptoms 3.

Withdrawal Management Protocol:

• Use Clinical Opiate Withdrawal Scale (COWS) to guide treatment intensity. Kratom withdrawal can produce COWS scores ranging from 14-31, with severe cases presenting with autonomic instability (BP 168/107, HR 115) 1, 2
• Consider low-dose buprenorphine induction ("microinduction") to minimize precipitated withdrawal risk, particularly valuable in the inpatient setting where patients may have recently used opioids 4
• Adjunctive symptomatic management should include:
  • Clonidine for autonomic symptoms (chills, diaphoresis, hypertension, tachycardia)
  • Gabapentin for restlessness, anxiety, and pain (300-900mg TID)
  • Hydroxyzine for anxiety and insomnia
  • Loperamide for gastrointestinal distress
  • Antiemetics as needed 1, 5

Critical pitfall: Standard urine toxicology will not detect kratom alkaloids—diagnosis relies on clinical history and presentation 1, 6. Do not dismiss withdrawal symptoms due to negative opioid screens.

Expected Timeline:

Kratom withdrawal typically resolves within 72-96 hours with appropriate management 1. However, synthetic kratom derivatives (7-hydroxymitragynine, mitragynine pseudoindoxyl) may produce more severe, rapid-onset withdrawal requiring more intensive treatment 1, 2.

Psychopharmacologic Regimen

Suicide Prevention and Mood Stabilization:

Implement cognitive behavioral therapy-based psychotherapy focused on suicide prevention during hospitalization 7. While the evidence for safety planning interventions alone is insufficient 7, CBT-based approaches targeting suicide prevention reduce suicide attempts in patients with recent suicidal behavior (within 6 months) 7.

Medication Strategy:

For depression and anxiety:

• Mirtazapine (15-45mg nightly) addresses multiple targets: depression, anxiety, insomnia, and treatment-emergent nausea from opioid medications 5. This is particularly relevant given this patient's reported sleep disturbance, variable appetite, and withdrawal-related gastrointestinal symptoms.
• Continue gabapentin beyond acute withdrawal phase for ongoing anxiety symptoms and neuropathic pain components

For bipolar disorder history:

• Exercise extreme caution with antidepressant monotherapy given reported history of irritability, impulsivity, elevated mood, and grandiosity
• If psychotic symptoms emerge (paranoia, concerns about others talking about him), strongly consider clozapine 7. Clozapine is the only medication with evidence for reducing suicide attempts in patients with schizophrenia/schizoaffective disorder and suicidal ideation 7
• Mood stabilizer consideration (lithium, valproate, or lamotrigine) may be warranted once diagnostic clarification occurs, though current presentation appears more consistent with substance-induced mood symptoms

Regarding ketamine: While ketamine infusion shows weak evidence for short-term reduction in suicidal ideation in major depressive disorder 7, there is insufficient evidence it reduces actual suicide attempts or deaths 7. Given this patient's polysubstance use history (methamphetamine, cannabis), ketamine's dissociative properties and abuse potential make it a poor choice in this clinical context.

Important Diagnostic Consideration:

Many of this patient's psychiatric symptoms may be substance-induced. Buprenorphine-naloxone treatment has been documented to resolve depression and anxiety symptoms in kratom-dependent patients, allowing discontinuation of antidepressants and anxiolytics within 4 months 3. Defer definitive bipolar disorder diagnosis until sustained abstinence is achieved.

Safety Planning and Suicide Risk Management

Immediate Safety Measures:

• Continuous observation or 1:1 monitoring until suicidal ideation fully resolves
• Remove access to lethal means (sharps, ligature points, medications)
• Assess suicide risk using validated tools: Columbia Suicide Severity Rating Scale Screener is recommended for general populations 7

Risk Assessment Domains (per VA/DOD guidelines):

Document the following 7:

• Self-directed violence history: Prior self-injurious behavior (last episode 2017)
• Current psychiatric symptoms: Depression with anhedonia, social isolation, poor concentration, guilt, shame; anxiety with excessive worry, intrusive thoughts, racing thoughts, panic
• Substance use: Active polysubstance use disorder (tobacco, cannabis, methamphetamine, oxycodone, hydrocodone, kratom)
• Social determinants: Identify protective factors (child, family support, personal determination)
• Physical health: Chronic pain, withdrawal symptoms

Critical evidence gap: There is insufficient evidence supporting formal risk stratification tools to determine "low/medium/high" suicide risk 7. Clinical judgment incorporating multiple domains guides disposition decisions.

Transition Planning:

Do not pursue opioid detoxification alone—this approach is associated with relapse and poor outcomes 4. Instead:

1. Continue buprenorphine-naloxone as maintenance treatment with linkage to outpatient medication for opioid use disorder (MOUD) program
2. Naltrexone transition may be considered once opioid-free interval is established (minimum 7-10 days). One case report demonstrated successful naltrexone initiation (including Vivitrol injection) without precipitating withdrawal after kratom cessation 1
3. Ensure timely outpatient follow-up (within 7 days) with integrated addiction psychiatry or dual diagnosis program
4. Coordinate with outpatient substance abuse treatment programs given prior participation

Polysubstance Use Considerations:

This patient's methamphetamine use history warrants specific attention:

• Screen for stimulant use disorder and withdrawal
• Assess for stimulant-induced mood symptoms
• Consider contingency management approaches for stimulant use disorder in outpatient setting

Monitoring and Reassessment

• Daily sedation and agitation assessment using Richmond Agitation-Sedation Scale 8
• Serial COWS assessments to guide buprenorphine dosing
• Daily suicide risk reassessment with documentation of ideation, intent, plan
• Monitor for opioid-induced side effects: respiratory depression, constipation, sedation 8
• Assess for buprenorphine-naloxone response on mood and anxiety symptoms over 3-7 days

Disposition criteria: Patient may transition to lower level of care (partial hospitalization, intensive outpatient, or residential) when:

• Withdrawal symptoms controlled (COWS <8)
• Suicidal ideation resolved with adequate safety planning
• Stable on buprenorphine-naloxone maintenance dose
• Outpatient MOUD and mental health follow-up secured
• Family/social support engaged